Key Highlights
- 4D Molecular Therapeutics Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales.
- The transactions involved 584 shares at prices between $6.49 and $14.
- The sales leave Bizily with a direct stake of 8,617 shares.
- The transaction was not accompanied by new clinical, regulatory, or Capital allocation news.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Chief Legal Officer Scott Bizily executed a sequence of option exercises and subsequent sales involving 584 shares at prices between $6.49 and $14.
What Happened
The transactions left Bizily with a direct stake of 8,617 shares. This transaction represents a routine insider adjustment and was not accompanied by any new data from clinical trials, regulatory updates, or capital allocation news.
Market Reaction
The disclosed information does not include stock price or trading data for 4D Molecular Therapeutics tied specifically to this insider transaction.
Outlook
The disclosed information does not include specific forward guidance beyond this routine insider transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.